Starna Therapeutics emerges with financing for mRNA vaccine and therapies

Kyle LaHucik

Senior Reporter

Starna Therapeutics has emerged with 150 million Yuan, or about $24 million, in Series A financing to take on two difficult areas in biotech R&D: RSV and idiopathic pulmonary fibrosis.

The Suzhou, China-based biotech secured the funds to move an mRNA vaccine for RSV into the clinic next year and a therapeutic for IPF sometime after that, CEO Rongkuan Frank Hu told Endpoints News. Hu was previously a general manager at RNA tech and services biotech GenePharma and, before that, a postdoc at UT Southwestern Medical Center. His co-founder is Qiang Cheng, a PI at Peking University, he said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Starna Therapeutics emerges with financing for mRNA vaccine and therapies

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

Senate bill targeting WuXi won't affect federal spending, CBO says

GSK unveils long-term Shingrix data as shingles competition heats up

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Star­na Ther­a­peu­tics emerges with fi­nanc­ing for mR­NA vac­cine and ther­a­pies

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

A ma­jor­i­ty of phar­ma and biotech com­pa­nies pro­hib­it Chat­G­PT use, sur­vey finds

Sen­ate bill tar­get­ing WuXi won't af­fect fed­er­al spend­ing, CBO says

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Starna Therapeutics emerges with financing for mRNA vaccine and therapies

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

Senate bill targeting WuXi won't affect federal spending, CBO says

GSK unveils long-term Shingrix data as shingles competition heats up

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24